Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BioSpaceBridgeBio Pharma plans to file for approval in the third quarter.Rare DiseaseRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) BioSpace BridgeBio Pharma plans to file for approval in the third quarter. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen trims Apellis pipeline and R&D team after $5.6bn takeoverNext: Zymeworks cuts deal to buy Theravance for $929m in cash Related Stories Clinical Data Pfizer drug acquired in Seagen deal disappoints in lung cancer study pharminent June 23, 2026 Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026
